Tag Archives: pricing

Part D Politics: Medicare Drug Rebates or Price Controls?

By Jill Wechsler | Published: February 20, 2013
Jill Wechsler Blog – PE Feb. 22, 2013 Part D Politics:  Medicare drug rebates or price controls? While health care was barely mentioned in the recent State of the Union address, President Obama generated some interest in his proposal to cut Medicare spending by reducing “taxpayer subsidies to prescription drug companies.” That’s code for requiring pharma marketers to pay [...]
Posted in Op-Ed, Regulatory, healthcare, pricing | Also tagged , , , | Leave a comment

Questions About the 2013 Implementation of IPAB

By Guest Blogger | Published: December 19, 2012
by Tom Norton With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun.  Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th.   A huge amount of activity, to be sure, but as stated, not surprising.  That’s because the law [...]
Posted in FDA, Legal, Market Access, Regulatory, healthcare, pricing | Also tagged , , , , , , | Leave a comment

Patients Wade into the European Pricing Debate

By Guest Blogger | Published: July 30, 2012
Patient groups are a growing force, not just in the debate around tactical areas of medical specialities, but also on the vital question of pricing and reimbursement rules. But will their voices be heard? Reflector reports. An important third party is struggling to make its voice heard in European pharma discussions. Drug pricing is not just [...]
Posted in Europe, Global, Guest Blog, Regulatory, healthcare, pricing | Also tagged , , , , | Leave a comment

Wins and Losses from Risk-Sharing Agreements

By William Looney | Published: November 17, 2010
Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is [...]
Posted in Europe, Global, Regulatory, Strategy, healthcare, pricing | Also tagged , , , , , | Leave a comment

NICE News or Bad News?

By William Looney | Published: November 3, 2010
Far from losing its mojo, the UK’s National Institute for Health and Clinical Excellence (NICE) will simply be sharing the stage with a range of new players under NHS reform — none of whom look supportive of the R&D industry. The big issue for industry in the UK this week is handicapping the future of its [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , , , , | Leave a comment